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Background
Ipilimumab (Yervoy) is a fully human antibody that
blocks CTLA-4 and has proven to extend overall survi-
val in patients with unresectable stage III or stage IV
melanoma [1]. Immune related adverse effects (IRAE)
are frequent and can be severe but are reversible with
early diagnosis and can be managed with corticosteroid
therapy [2]. Most of the recently published immune
monitoring studies focus mainly on the effect that ipili-
mumab has on T cell populations[3]. To date, little
information is available on the possible impact that ipili-
mumab treatment may have on MDSC populations and
their suppressive mechanisms[4]. In order to evaluate
these effects, we conducted an in-depth immune moni-
toring study centered on peripheral blood MDSC popu-
lations as well as T cells in advanced melanoma patients
undergoing treatment with ipilimumab.
Materials and methods
Fourteen patients with advanced stage melanoma
received ipilimumab treatment at 3 mg/kg or 10 mg/kg
doses and six of which were part of an ongoing double
blind randomized trial (Bristol-Myers Squibb trial
CA184-169). Blood samples were collected from each
patient before treatment (baseline) and at the time of
the second and fourth ipilimumab doses (3 and 9 weeks
after the first dose). Peripheral blood mononuclear cells
were isolated by density gradient centrifugation and
stained for multicolored flow cytometric analysis. The
staining protocol included five 9-color panels to analyze
T cells (relative frequencies, activation, memory and
Tregs) and MDSCs.
Results
Absolute lymphocyte counts showed an increasing trend
during the course of treatment without significant differ-
ences. Analysis of circulating Treg (CD4+ CD25+
CD127lo FoxP3+) frequencies revealed an initial increase,
significantly decreasing after the second ipilimumab dose
(week 9). The endpoint mean frequency of Tregs was
lower than the baseline. Changes in MDSC populations
with granulocytic and monocytic phenotype (Lin- HLA-
DR-/lo CD15+ CD33+ CD11b+ and Lin- HLA-DR-/lo
CD14+, respectively) were monitored and the results
showed that, after the first dose, the granulocytic MDSC
population significantly decreased, remaining low at
week 9. This decrease was accompanied by a significant
decrease in the population of ARG1+ myeloid cells.
Conclusion
The results shown in this work provide a first look at the
early responses of peripheral blood myeloid cell popula-
tions to ipilimumab treatment. The mechanisms by which
these in trans effects are taking place should be further
explored as well as their possible relations to clinical
benefit.
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